Odyssey Therapeutics, Inc.

Cosa ha dichiarato Odyssey Therapeutics, Inc. il 4 agosto 2026

Dal 8-K dell’azienda.

Conference call sui risultati

Per Odyssey Therapeutics, Inc. non è disponibile alcuna trascrizione di conference call sui risultati.

Cosa ha detto il management

“Positive clinical proof-of-concept data for OD-001 marked an important milestone for Odyssey and we look forward to sharing additional, supportive data from this trial in October,”

Citato alla lettera dal comunicato, e mostrato solo quando il documento lo attribuisce a una persona con nome e cognome.

Come ha reagito il prezzo

I comunicati escono dopo la chiusura o prima dell’apertura, quindi il movimento è quello della seduta successiva.

Cosa fa Odyssey Therapeutics, Inc.

Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.

La descrizione dell’azienda stessa, come compare in calce al comunicato.